ASMB - Company ID 0001426800
ASSEMBLY BIOSCIENCES, INC. trades as ASMB. In its fiscal 2025 annual report the company posted revenue of $72.30M, up 153.5% from the prior year and net income of -$6.12M. This page tracks ASSEMBLY BIOSCIENCES, INC. through 872 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -474.7% to -8.5% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-27 |
| SCHEDULE 13D/A | - | 2026-05-27 |
| Major company event | 8-K | 2026-05-26 |
| Prospectus supplement | 424B5 | 2026-05-26 |
| Prospectus supplement | 424B5 | 2026-05-22 |
| Major company event | 8-K | 2026-05-22 |
| SCHEDULE 13G | - | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-07 |
The largest companies sharing ASSEMBLY BIOSCIENCES, INC.'s SEC industry classification (pharmaceutical preparations).
ASSEMBLY BIOSCIENCES, INC. reported revenue of $72.30M for fiscal year 2025, an increase of 153.5% year over year.
In its latest fiscal year ASSEMBLY BIOSCIENCES, INC. reported a net loss of $6.12M.